BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of “Moderate Buy” from Brokerages

BeiGene, Ltd. (NASDAQ:BGNE) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $241.21.

Several equities research analysts have commented on BGNE shares. Bank of America lowered their price target on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. JPMorgan Chase & Co. increased their target price on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. JMP Securities began coverage on shares of BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 target price on the stock. Finally, Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th.

BeiGene Price Performance

Shares of BeiGene stock opened at $239.38 on Friday. BeiGene has a one year low of $126.97 and a one year high of $248.16. The stock’s fifty day moving average is $201.44 and its 200 day moving average is $170.48. The stock has a market cap of $23.20 billion, a P/E ratio of -31.62 and a beta of 0.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The firm had revenue of $929.20 million for the quarter, compared to analysts’ expectations of $810.34 million. During the same period in the previous year, the firm posted ($3.64) earnings per share. The business’s revenue was up 56.1% compared to the same quarter last year. Sell-side analysts anticipate that BeiGene will post -5.13 earnings per share for the current year.

Insider Buying and Selling at BeiGene

In other news, SVP Chan Henry Lee sold 834 shares of BeiGene stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total value of $133,915.38. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total value of $133,915.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Oyler sold 6,175 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,904 shares of company stock worth $5,034,965. 7.43% of the stock is owned by company insiders.

Institutional Trading of BeiGene

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James & Associates boosted its position in shares of BeiGene by 0.4% during the 2nd quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock valued at $3,035,000 after purchasing an additional 76 shares in the last quarter. Truist Financial Corp lifted its stake in shares of BeiGene by 10.1% in the second quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock worth $217,000 after buying an additional 140 shares during the last quarter. Parkwood LLC increased its position in BeiGene by 3.0% during the fourth quarter. Parkwood LLC now owns 6,464 shares of the company’s stock worth $1,166,000 after acquiring an additional 191 shares during the period. ProShare Advisors LLC increased its position in BeiGene by 8.1% during the first quarter. ProShare Advisors LLC now owns 2,902 shares of the company’s stock worth $454,000 after acquiring an additional 217 shares during the period. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in BeiGene by 51.5% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after buying an additional 279 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.